2017 American Transplant Congress
Pre-Operative Desensitization for Live Donor Liver Transplantation with Strong Donor-Specific Antibodies.
Background: Presence of strong donor-specific antibodies (DSA) (MFI>4000) likely results in uncomplicated short-term outcome in whole liver transplants due to absorption of DSA by the…2017 American Transplant Congress
Treating Refractory Liver Allograft Rejection with Photopheresis.
DSAs with persistent high titer alloantibodies are associated with refractory antibody mediated rejection (AMR) and liver injury.METHODS: We present 4 liver transplant (LT) patients refractory…2017 American Transplant Congress
Graft Survival in De Novo Donor-Specific Antibodies and Positive Flow Crossmatch Kidney Transplants Is influenced by Class I and Class II.
Patients with de novo donor-specific antibodies (dnDSA) show inferior graft survival in numerous small studies. We assessed the effect of dnDSA on graft and patient…2017 American Transplant Congress
Pre-Transplant HLA-Specific B Cell Breadth of Reactivity in a Novel Multiplex Bead-Based Assay Predicts Rejection in Kidney Transplant Recipients.
1Northwestern University, Chicago; 2Icahn School of Medicine at Mount Sinai, New York
Introduction: Recipients with broad sensitization to HLA defined by a high percentage of Panel Reactive Antibodies (PRA) are at higher immunologic risk for poor graft…2017 American Transplant Congress
Outcomes of 100 ABO Incompatible Kidney Transplants: A Single US Center Experience.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
IntroductionAcceptable patient and graft outcomes of ABO incompatible (ABOi) living donor kidney transplantation (LDKT) have been reported with the use of desensitization strategies. Data on…2017 American Transplant Congress
Eliminating False Positive Virtual Crossmatch Results for Lung Transplant Candidates by Using Multiple Antibody Testing Platforms.
Purpose: At present, immunologic risk for lung transplant patients is evaluated based on Virtual crossmatch (VXM) by comparing recipient's HLA antibodies detected by Single antigen…2017 American Transplant Congress
Timing of HLA Testing as a Means of Reducing Cost and Increasing Efficiency of Living Kidney Donation.
Medicine, University of Rochester Medical Center, Rochester, NY
Purpose: Creating an effective living kidney donor process can be a challenge for transplant centers. There needs to be a balance between efficiency, resources, patient…2017 American Transplant Congress
Incidence of De Novo Donor-Specific Antibodies Following Kidney Transplantation.
With a range of frequencies reported in several small studies, true incidence of de novo donor-specific human leukocyte antigen (HLA) antibodies (dnDSA) is unknown. As…2017 American Transplant Congress
Effect of Preformed Donor-Specific Antibodies in Intestine/Multivisceral Transplantation.
Aim: To analyze the effect of preformed donor-specific antibodies (DSA) in intestine/multivisceral transplantation patients.Methods: Retrospective review of preformed and de novo DSAs of all intestine/multivisceral…2017 American Transplant Congress
Outcome of Living-Donor Kidney Transplantation in Cross-Match-Positive Recipients at a Single Center.
BackgroundLiving-donor kidney transplantation in cross-match (XM)-positive patients remains high-risk and requires an optimal desensitization protocol. We started a desensitization protocol for XM-positive patients in January…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 47
- Next Page »